Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

89.68

+1.87

+2.13%

盘后89.68

+0.000.00%

19:59 EST

High91.38	Low86.35	Vol1.86M
Open90.09	D1 Closing87.81	Amplitude5.73%
Mkt Cap7.08B	Tradable Cap4.90B	Total Shares78.95M
T/O166.66M	T/O Rate3.41%	Tradable Shares54.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":89.68,"timestamp":1765573200000,"preClose":87.81,"halted":0,"volume":1863806,"hourTrading":{"tag":"盘后","latestPrice":89.68,"preClose":89.68,"latestTime":"19:59 EST","volume":243332,"amount":21821890.1605,"timestamp":1765587591323},"delay":0,"floatShares":54626600,"shares":78949027,"eps":-3.597465,"marketStatus":"Market Closed","change":1.87,"latestTime":"12-12 16:00:00 EST","open":90.09,"high":91.38,"low":86.35,"amount":166661961.19538,"amplitude":0.057283,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.597465,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":87.81,"preHourTrading":{"tag":"盘前","latestPrice":90.88,"preClose":87.81,"latestTime":"09:29 EST","volume":5318,"amount":484887.42254,"timestamp":1765549799999},"postHourTrading":{"tag":"盘后","latestPrice":89.68,"preClose":89.68,"latestTime":"19:59 EST","volume":243332,"amount":21821890.1605,"timestamp":1765587591323},"volumeRatio":0.5792599684283538,"impliedVol":0.6592,"impliedVolPercentile":0.288},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"2591682050","title":"Director Bruce Booth Reports Disposal of Kymera Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591682050","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591682050?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:37","pubTimestamp":1765582671,"startTime":"0","endTime":"0","summary":"Bruce Booth, Director, reported a disposal of common shares of Kymera Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6p7tXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Bruce Booth Reports Disposal of Kymera Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2590506522","title":"S&P 500 Futures Drop In Premarket Trading; Fermi, Broadcom Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506522","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590506522?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:31","pubTimestamp":1765542660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, lululemon athletica inc.  was up 9.1% in pre-market trading, and Coeur Mining Inc.  was up 4.6%.Kymera Therapeutics Inc. , New Gold Inc. , and Hecla Mining Co.  were all posting gains of at least 4%. In early trading, Fermi Inc.  and Broadcom Inc.  had posted declines, falling 33.1% and 5.8%, respectively.Meanwhile S&P 500 futures were down 0.15%, with futures for the Dow Jones Industrial Average rising 0.21%. The Cboe Volatility Index futures were down 3.65%.In commodities news, Brent crude oil futures were down 0.23%, while gold futures were up 1.32%. Bitcoin climbed 0.53% to $92,300.In the previous regular trading session, the S&P 500 and the Dow were up 0.21% and 1.34%, respectively. Stocks in Asia were up overnight, with Japan's NIKKEI 225 Index up 1.37% and China's Shanghai Composite Index rising 0.41%.U.S. stock markets open for tradi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","LU1992135472.HKD","IE0001KFT4U8.USD","LU2041044095.USD","LU0345770308.USD","ESmain","LU0642271901.SGD","LU2237443895.HKD","LU2092937221.SGD","LU1989764748.USD","MESmain","LU0472753341.HKD","LU0215105999.USD","LU2133065610.SGD","IVV","LU0823434740.USD","LU2272731782.SGD",".SPX","LU0256863902.USD","LU1223082519.USD","LU2746668461.USD","VOO","LU1974910355.USD","SPXU","OEF","UPRO","AVGO","NGD","CDE","LU2168564495.EUR","SH","FRMI","SDS","IE00BZ9MQY76.HKD","LU0689626769.HKD","BK4570","KYMR","SPY","SSO","OEX","LU0061475181.USD","BK4566","IE0004445015.USD","LU1629891620.HKD","SG9999001424.SGD","LU2211814178.USD","BK4222","LU1037948897.HKD","LU1803068979.SGD"],"gpt_icon":1},{"id":"2590541309","title":"Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541309","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541309?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:20","pubTimestamp":1765488016,"startTime":"0","endTime":"0","summary":"Baker Bros. Advisors LP reported an acquisition of common shares of Kymera Therapeutics Inc. . The filing lists Felix J. Baker, Director of Kymera Therapeutics, as well as Baker Bros. Advisors LP and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2xLS7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590541517","title":"Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541517","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541517?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Dec.  11, 2025  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204288/0/en/Kymera-Therapeutics-Announces-Closing-of-Upsized-602-Million-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1244550221.USD","LU1363072403.SGD","LU0006306889.USD","BK4127","LU0158827781.USD","LU0234570918.USD","LU1791710400.SGD","LU2089283258.USD","LU1989772840.SGD","LU2357305700.SGD","KYMR","LU1548497426.USD","LU1989772923.USD","LU1720051108.HKD","LU1791710582.SGD","LU1162221912.USD","LU0314104364.USD","LU0158827948.USD","LU2089284900.SGD","LU0795875086.SGD","BK4585","BK4139","LU0106261372.USD","LU0098860793.USD","BK4516","BK4581","LU0971096721.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU0912757837.SGD","LU2271345857.HKD","BK4504","LU2111349929.HKD","BK4534","LU2028103732.USD","LU1720051017.SGD","LU0225283273.USD","LU1732800096.USD","LU0795875169.SGD","LU2347655156.SGD","LU1668664300.SGD","LU2133065610.SGD","LU0320765646.SGD","LU1244550494.USD","LU0557290698.USD","LU1732799900.SGD","LU0528227936.USD","LU0267386448.USD","LU0882574139.USD"],"gpt_icon":0},{"id":"2590448518","title":"FDA Grants Fast Track Designation to Kymera Therapeutics’ KT-621 for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590448518","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590448518?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454431,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis. This designation is based on positive results from the KT-621 BroADen Phase 1b trial in atopic dermatitis patients. Fast Track status is expected to facilitate the development and expedite the review process for KT-621. The ongoing BROADEN2 Phase 2b trial for atopic dermatitis is expected to report data by mid-2027, and a Phase 2b trial in asthma is set to begin in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLhJMvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014039.USD","LU0314104364.USD","SG9999014005.SGD","BK4585","KYMR","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","BK4139","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2590518907","title":"Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518907?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUABV3SHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590451815","title":"Kymera Therapeutics Inc - KT-621 Phase 2B Ad Trial Data Expected by Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590451815?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUABV3SHL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590761590","title":"Kymera Therapeutics Inc : Mizuho Raises Target Price to $120 From $81","url":"https://stock-news.laohu8.com/highlight/detail?id=2590761590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590761590?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:40","pubTimestamp":1765453243,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2590353984","title":"Kymera Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590353984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590353984?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:08","pubTimestamp":1765382880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 11:08 ET (16:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"gpt_icon":0},{"id":"2590370811","title":"BRIEF-Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590370811","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590370811?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:31","pubTimestamp":1765341073,"startTime":"0","endTime":"0","summary":"BRIEF-Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per ShareDec 9 (Reuters) - Kymera Therapeutics Inc KYMR.O:KYMERA THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $6","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA79TXS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2590637081","title":"Kymera Therapeutics Inc - Selling 7,000,000 Shares at $86 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590637081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590637081?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:30","pubTimestamp":1765341000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA79TXS7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590377087","title":"Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590377087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590377087?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:30","pubTimestamp":1765341000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA79TXS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590341181","title":"Kymera Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $134 From $84","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341181?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:42","pubTimestamp":1765287762,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nAZN4RCE0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590734159","title":"Kymera Therapeutics Shares Down 3.9% Premarket After Climbing 41.5% in Previous Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2590734159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590734159?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:38","pubTimestamp":1765287527,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF13V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590341339","title":"Kymera Therapeutics : Oppenheimer Raises Target Price to $120 From $67","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341339?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:31","pubTimestamp":1765287112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nAZN4RCH7P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590534924","title":"Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534924","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534924?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:19","pubTimestamp":1765286381,"startTime":"0","endTime":"0","summary":"Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","KYMR"],"gpt_icon":0},{"id":"2590343403","title":"Kymera Therapeutics Inc : Truist Securities Raises Target Price to $116 From $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343403?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:02","pubTimestamp":1765281723,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590572343","title":"Kymera Therapeutics Inc : Bofa Global Research Raises Price Objective to $112 From $71","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590572343?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:56","pubTimestamp":1765281361,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2590343510","title":"Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343510","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343510?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:55","pubTimestamp":1765281306,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $100.05, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR"],"gpt_icon":0},{"id":"2590172743","title":"Kymera Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590172743","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590172743?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:41","pubTimestamp":1765276860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 05:41 ET (10:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.3461},{"period":"1month","weight":0.4116},{"period":"3month","weight":0.9085},{"period":"6month","weight":0.9097},{"period":"1year","weight":1.1266},{"period":"ytd","weight":1.2292}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.085982},{"month":2,"riseRate":0.2,"avgChangeRate":-0.068972},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073393},{"month":4,"riseRate":0.6,"avgChangeRate":0.013164},{"month":5,"riseRate":0.2,"avgChangeRate":-0.147131},{"month":6,"riseRate":0.6,"avgChangeRate":0.114241},{"month":7,"riseRate":0.8,"avgChangeRate":0.172329},{"month":8,"riseRate":0.6,"avgChangeRate":0.035263},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.123403}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction